Cited by 963Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmune Cell Function and Interaction

The DOI matches its Crossref record; 157 of the 159 references it cites were found in a registry or an index.

TIM3 comes of age as an inhibitory receptor

Open access

Wolf, Yochai, Anderson, Ana C., Kuchroo, Vijay K.·2020·Nature Reviews Immunology

DOI 10.1038/s41577-019-0224-6PMC PMC7327798

Open this paper in CoChat — free account Open PDF

Abstract

T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and CD8+ T cells. Initial data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the lack of a definable inhibitory signalling motif, it was also suggested that TIM3 might act as a co-stimulatory receptor. Recent studies have shown that TIM3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which are co-expressed and co-regulated on dysfunctional or 'exhausted' T cells in chronic viral infections and cancer. Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell responses in patients with advanced cancers. Here, we highlight the developments in understanding TIM3 biology, including novel ligand identification and the discovery of loss-of-function mutations associated with human disease. In addition, we summarize emerging data from human clinical trials showing that TIM3 indeed acts as a 'checkpoint' receptor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41577-019-0224-6

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citation
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citation
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citation
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Show all 159 references

Research works printed but not linked: 2

Weiss, G. J. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J. Immunother. Cancer 5, 86 (2017).
Davar, D. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J. Immunother. Cancer 6, 115 (2018).

Sorted by citations

Items 601–700 of 963

Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE
Dreveton, L. S., Spencker, J. J., Rincón-Arévalo, H., Aue, A., Osmanodja, B., Wiedemann, A., Szelinski, F., Krönke, G., Dorner, T. E., Schrezenmeier, E. V., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1685275 · Cited by 5
Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response
Edwards, J. M., Senthi, S., Smith, R., Burridge, H., Owens, C., Shackleton, M. J., Andrews, M. C., & van Zelm, M. C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012317 · Cited by 5
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 8
Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment
Zhu, D., Zhu, Y., Yang, X., Gao, L., Zhang, Z., Xu, X., Dong, L., Zhang, H., Yun, Z., Yang, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114367 · Cited by 7
Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors
Alamán‐Díez, P., Ferrer-Royo, S., Oñate, C., Compaired, P. M., Balsas, P., Pardo, J., Garcia-Aznar, J. M., & González‐Loyola, A. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.01.050 · Cited by 5
Dual immune checkpoint blockade strategies for cancer therapy
Liu, Y., Yadav, U. P., Chen, C., & Wang, P. (2026) · Cell investigation. · doi:10.1016/j.clnves.2026.100064 · Cited by 7
Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice
Zhang, X., Gao, Y., Hu, W., Liang, Y., Yin, X., Shi, X., Li, H., Liao, H., Guo, J., Yu, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70876-4 · Cited by 6
From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy
Wijnen, S. C. M. A., Dimitriadis, P., Wessels, L. F. A., & Blank, C. U. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116711 · Cited by 5
Expression and Clinical Significance of Peripheral Blood IL-17A, IL-22, Tim-3, and gal-9 in Children with Infectious Mononucleosis
Xu, M., Li, Y., Cao, M., Su, Y., Ji, Z., & Zhou, W. (2023) · Viral Immunology · doi:10.1089/vim.2022.0203 · Cited by 5
Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy
Ma, Y., Xu, X., Wang, H., Liu, Y., & Piao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228331 · Cited by 5
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors
Lee, J., & Lathia, J. D. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.016 · Cited by 5
Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell RNA-seq analysis
Xian, W., Asad, M., Wu, S., Bai, Z., Li, F., Lu, J., Zu, G., Brintnell, E., Chen, H., Mao, Y. Q., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1017-7 · Cited by 5
Integrated bioinformatic analysis and experimental validation for exploring the key immune checkpoint of COPD
Ke, J., Huang, S., He, Z., Lei, S., Lin, S., & Duan, M. (2024) · Gene · doi:10.1016/j.gene.2024.148711 · Cited by 5
TIM‐3 Expression in Endometriosis
Reis, J. L., Martins, C. G., Ângelo‐Dias, M., Rosa, N. N., Borrego, L. M., & de Lima, J. J. A. V. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13887 · Cited by 5
Genetics of Acquired Cytokine Storm Syndromes
Schulert, G. S., & Zhang, K. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_8 · Cited by 5
Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins
Tang, C., Dong, Z., Shi, Y., Liu, B., Wang, Z., Cheng, L., Liu, F., Sun, H., Du, Y., Pan, L., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116748 · Cited by 5
Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Kong, H., Yang, Q., Wu, C.-W. G., Wu, X., Yan, X., Huang, L., Chen, L., Zhou, Z., Wang, P., & Jiang, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0270 · Cited by 5
The Functional Role and Prognostic Significance of TIM-3 Expression on NK Cells in the Diagnostic Bone Marrows in Acute Myeloid Leukemia
Sun, K., Shi, Z.-Y., Xie, D., Wang, Y., Jiang, H., Jiang, Q., Huang, X.-J., & Qin, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12122717 · Cited by 5
Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function
Wang, S., Wang, Y., Guan, L.-S., Shen, A., Huang, R.-J., Yuan, S., Xiao, Y.-L., Wang, L., Lei, D., Zhao, Y., et al. (2025) · BMC Medical Genomics · doi:10.1186/s12920-024-02082-4 · Cited by 6
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances
McLaughlin, Q., Sojka, D. K., Kennedy, K. J., Piersma, S. J., & Sethakorn, N. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03503-7 · Cited by 6
A Novel Risk Score Model Based on Eleven Extracellular Matrix-Related Genes for Predicting Overall Survival of Glioma Patients
Li, X., Wang, Y., Wu, W., Xiang, J., Qi, L., Wang, N., Wang, M., & Yu, H. (2022) · Journal of Oncology · doi:10.1155/2022/4966820 · Cited by 5
Response Challenges to Cancer Immunotherapies
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v2i.65 · Cited by 5
Nanoparticle accumulation in liver may induce resistance to immune checkpoint blockade therapy
Dai, H., Yang, Q., Sun, R., Zhang, Y., Ma, Q., Shen, Y., Wang, B., Chen, Y., Xu, J., Tian, B., et al. (2022) · Nano Research · doi:10.1007/s12274-022-5142-4 · Cited by 5
The poly(C)-binding protein Pcbp2 is essential for CD4+ T cell activation and proliferation
Martinelli, M., Aguilar, G., Lee, D. S. M., Kromer, A., Nguyen, N., Wilkins, B. J., Akimova, T., Beier, U. H., & Ghanem, L. R. (2022) · iScience · doi:10.1016/j.isci.2022.105860 · Cited by 5
Transcriptomic and Functional Evidence That miRNA193a-3p Inhibits Lymphatic Endothelial Cell (LEC) and LEC + MCF-7 Spheroid Growth Directly and by Altering MCF-7 Secretome
Azzarito, G., Henry, M., Rotshteyn, T., Leeners, B., & Dubey, R. K. (2023) · Cells · doi:10.3390/cells12030389 · Cited by 5
Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer
Zhao, Y., Liu, H., Qi, Z., Jin, H., Wang, Y., Wang, H., Huang, B., Huang, F., Jia, X., Wang, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63325-z · Cited by 5
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
Ota, Y., Inagaki, R., Nagai, Y., Hirose, Y., Murata, M., & Yamamoto, S. (2024) · BMC Immunology · doi:10.1186/s12865-024-00643-x · Cited by 5
Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma
Ammons, D. T., Harris, R. A., Chow, L., & DOW, S. W. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03950-3 · Cited by 6
Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy
Ren, X., Guo, A., Geng, J., Chen, Y., Wang, X., Zhou, L., & Shi, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544104 · Cited by 6
Breaking the Triad: Immune Tolerance Induction Without Antigen Co-Presentation via Tim Agonist for the Treatment of Autoimmune Diseases
Karzoun, B., Ramadan, A. M., Allababidi, S., & Fathallah, A. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125531 · Cited by 5
Proteomic Analysis of Differentially Expressed Proteins in the Placenta of Anticardiolipin Antibody‐ (ACA‐) Positive Pregnant Mice after Anzi Heji Treatment
Xie, Y., & Lu, Q. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1967698 · Cited by 5
Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein
Jarahian, M., Marstaller, K., Banna, N., Ahani, R., Etemadzadeh, M. H., Boller, L. K., Azadmanesh, K., Cid-Arregui, Á., Khezri, A., Berger, M. R., et al. (2021) · Journal of Innate Immunity · doi:10.1159/000517628 · Cited by 5
Immune signature as a potential marker for predicting response to immunotherapy in obesity‐associated colorectal cancer
Park, S., An, J., Ha, S. Y., Nam, S., & Kim, J. H. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15909 · Cited by 5
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
Gaißler, A., Meldgaard, T. S., Heeke, C., Babaei, S., Tvingsholm, S. A., Bochem, J., Spreuer, J., Amaral, T. M. S., Wagner, N. B., Klein, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906352 · Cited by 7
Non-small cell lung cancer in the era of immunotherapy
Huang, Q., Kemnade, J. O., Cornwell, L., Kheradmand, F., Sabichi, A. L., & Das, D. G. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.009 · Cited by 6
Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy
Kikushige, Y. (2022) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2022-010 · Cited by 4
A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer
Zhong, M., Huang, Z.-P., Wang, X., Cai, D., Li, C., Gao, F., Wu, X., & Wang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.902974 · Cited by 5
C chemokines are prognostic biomarkers correlated with diverse immune cell infiltrations in clear cell renal cell carcinoma
Chen, Z., Wu, R., Ma, J., & Zheng, J. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-424 · Cited by 5
Targeting the hippo pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Meng, Y. G., Chang, X., Cao, S., Ma, P., Ouyang, Y. Q., & Dong, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115067 · Cited by 4
Anti-atherogenic immune checkpoint TIM-3 as a promising pharmacologic target toward ischemic heart diseases: a prospective review
Rezabakhsh, A., Safaei, N., Nabavi, S. M., Roosta, Y., Giampieri, F., & Battino, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10729-3 · Cited by 4
TIM-3, a potential target for sepsis therapy
Huang, S., Huang, X., Feng, X., Wang, R., Liao, F., Liu, D., Sun, J., Zhang, H., Yu, A., & Zeng, L. (2025) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2025.08.001 · Cited by 4
Proteostasis of immune checkpoint receptors
Tey, P. Y., Urbé, S., & Clague, M. J. (2025) · Biochemical Journal · doi:10.1042/bcj20253299 · Cited by 4
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes
Lilljebjörn, H., Peña‐Martínez, P., Thorsson, H., Henningsson, R., Rissler, M., Landberg, N., Puente‐Moncada, N., von Palffy, S., Rissler, V., Staněk, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66546-6 · Cited by 6
Dynamics of checkpoint receptors in γδ T cell subsets are associated with clinical response during anti-PD-1 immunotherapies
Tardos, E. C., Dachicourt, L., Baglioni, M. V., da Silva, M. G. F. F., Secci, D., Donia, M., Kverneland, A. H., Svane, I. M., & Bekiaris, V. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00338-9 · Cited by 4
Immunotherapy and targeted therapy for high grade gliomas: current and future directions
Hsueh, B., Steuart, S. J., Odukoya, A. O., Prager, B. C., Kim, Y. J., Hill, C. M., Choi, B. D., & Dunn, G. P. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05315-3 · Cited by 5
Proteomics Analysis of Plasma for Risk of Sepsis: Findings from the Atherosclerosis Risk in Communities Study
Ishigami, J., Hu, X. F., Schlosser, P., Austin, T. R., Chen, J., Psaty, B. M., Dowdy, D. W., Ballantyne, C. M., Grams, M. E., Coresh, J., et al. (2025) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaf179 · Cited by 4
The role of the TIM-3 receptor in inflammatory bowel disease and autoimmunity: implications for TIM-3 and TCR crosstalk
Gabel, M., Knauss, A., Neurath, M. F., & Weigmann, B. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02631-z · Cited by 3
TIM-3+ Macrophages: Insights into Their Role in Cancer and Inflammation
Maksimova, А. А., Викторовна, Т. Т., & Chernykh, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020840 · Cited by 4
Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma
Zhang, S., Liu, J., & Li, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1696105 · Cited by 5
Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer
Wang, X., Zhu, C., Sun, Y., Xie, X., Wang, M., Jin, Y., Gu, Y., Qian, L., Shi, L., Xu, J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013656 · Cited by 4
Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies
Gezici, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00035-4 · Cited by 4
Porcine TLR8 signaling and its anti-infection function are disturbed by immune checkpoint receptor TIM-3 via inhibition of P13K-AKT pathway
Zheng, W., Ao, D., Cao, Q., Liu, A., Lv, M., Sun, Z., Zhang, H., Zheng, W., Chen, N., & Zhu, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132018 · Cited by 4
Molecular Hydrogen Therapy in Aneurysmal SAH With RA and Newly-diagnosed SLE, Complicated With Acute Ischemic Infarction: A Case Report of Improved Immune Markers Including Tr1 Cells, Breg Cells and TIM3 Expression on Tc Cells
CHEN, J.-Y., Lu, J., FENG, S.-W., Ho, Y., LUI, S.-W., HSIEH, T.-Y., & Liu, F. (2024) · In Vivo · doi:10.21873/invivo.13799 · Cited by 4
The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion
Poggi, A. D., Matis, S., Uras, C. R. M., Raffaghello, L., Benelli, R., & Zocchi, M. R. (2025) · Biomolecules · doi:10.3390/biom15060866 · Cited by 4
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment
Budagova, T., Efremova, A. S., Maiak, M. A., & Goldshtein, D. V. (2025) · Cells · doi:10.3390/cells14231858 · Cited by 4
Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
Tsai, C., Chi, H., Wu, R., Weng, C., Tai, T.-S., Lin, C., Chen, T., Wang, Y., Chou, L., Hsu, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines10010008 · Cited by 4
Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
Jiang, H., Shin, D. H., Yi, Y., Fan, X., Gumin, J., He, J., Gillard, A. G., Lang, F. F., Gomez‐Manzano, C., & Fueyo-Margareto, J. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0054 · Cited by 4
Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination
Hsieh, M.-C., Yu, W., Weng, C.-C., Chen, W., Chen, C.-K., Lee, Y., & Chen, M. (2023) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000969 · Cited by 4
Synergistic effects of immune checkpoints and checkpoint inhibitors in inflammatory neuropathies: Implications and mechanisms
Sarkar, A., Nagappa, M., Dey, S., Mondal, S., Babu, G. S., Choudhury, S. P., Akhil, P., & Debnath, M. (2023) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12605 · Cited by 4
Evaluating targeted therapies in older patients with TP53 -mutated AML
Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4
Inhibitory Checkpoint Receptor TIM-3 as a Regulator of the Functional Activity of Dendritic Cells
Викторовна, Т. Т., & Chernykh, E. R. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06175-z · Cited by 4
Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble
Chang, X., & Miao, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407403 · Cited by 4
Immune responses and immunotherapeutic approaches in the treatment against cancer
Leong, S. P. L. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10300-7 · Cited by 4
Exploration of protein and genetic targets causing atrioventricular block: mendelian-randomization analyses based on eQTL data and pQTL data
Wang, T., Ma, P., Wang, X., & Xia, Y. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04209-y · Cited by 4
Fyn, an important molecule in the brain, is a potential therapeutic target for brain tumours
Xu, C., Tang, Y. P., Lu, X., & Chen, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1485919 · Cited by 4
Immunotherapy for Renal Cell Carcinoma—What More is to Come?
Yochum, Z. A., & Braun, D. A. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01143-7 · Cited by 5
Maximizing insights from monogenic immune disorders
Barmada, A., Ramaswamy, A., & Lucas, C. L. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.09.008 · Cited by 4
Rapamycin relieves lupus nephritis by regulating TIM-3 and CD4+CD25+Foxp3+ Treg cells in an MRL/lpr mouse model
Gao, Y., Fan, X.-Z., Li, R., & Zhou, X. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.118778 · Cited by 4
Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysis
Lü, J., Zheng, G., Dong, A., Chang, X., Cao, X., Liu, M., Shi, X., Wang, C., Yang, Y., & Jia, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.990034 · Cited by 4
Downregulation of AT ‐rich interaction domain 2 underlies natural killer cell dysfunction in oral squamous cell carcinoma
Li, W., An, N., Wang, M., Liu, X., & Mei, Z. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12602 · Cited by 5
Radiotherapy upregulated immune checkpoints contribute to the development of second primary OSCC
Wang, L., Wang, S., Zhang, J., Peng, J., Cheng, B., Li, H., & Hu, Q. (2023) · Oral Diseases · doi:10.1111/odi.14621 · Cited by 4
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
Lameris, R., Shahine, A., Veth, M., Westerman, B. A., Godfrey, D. I., Hulsik, D. L., Brouwer, P., Rossjohn, J., de Gruijl, T. D., & van der Vliet, H. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007631 · Cited by 4
A pan-cancer analysis of the prognostic implication and oncogenic role of tubulin epsilon and delta complex 2 (TEDC2) in human tumors
Liu, Y., Zhu, J., Shen, J., Lu, Y., Pan, K., Tong, C., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272108 · Cited by 4
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma
Kgokolo, M., Malinga, N. Z., Steel, H. C., Meyer, P. W. A., Smit, T., Anderson, R., & Rapoport, B. L. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101867 · Cited by 4
Dr Jekyll and Mr Hyde: From Two Branches of Immune Response to Three Types of Interferon ResponsePreprint
Brown, B. (2023) · Qeios · doi:10.32388/pbxuf5 · Cited by 4
A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets
Singh, A., Miranda Bedate, A., von Richthofen, H. J., Vijver, S. V., van der Vlist, M., Kuhn, R., Yermanos, A., Kuball, J. J., Kesmir, C., Pascoal Ramos, M. I., et al. (2024) · eLife · doi:10.7554/elife.92870 · Cited by 4
Modulation of galectin-9 mediated responses in monocytes and T-cells by pregnancy-specific glycoprotein 1
Mendoza, M., Ballesteros, Á., Rendon-Correa, E., Tonk, R., Warren, J., Snow, A. L., Stowell, S. R., Blois, S. M., & Dveksler, G. S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107638 · Cited by 3
Neighborhood clustering analysis to define epithelial–stromal interface for tumor infiltrating lymphocyte evaluation
Yeung, T., Zhang, Y., Zhou, Q., & Burack, R. (2025) · Journal of Pathology Informatics · doi:10.1016/j.jpi.2025.100465 · Cited by 3
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing
Hafezi, M., Genolet, R., Hadadi, L., Chap, B. S., Bobisse, S., Attianese, G. M. P. G., Jorfi, H. E., Cropp, D., Pericou, L., Arnaud, M., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201041 · Cited by 3
The clinical characteristics, mechanism and management of immune checkpoint inhibitor-related arthritis
Gao, J., Miao, J., Zhinan, C., & Zhu, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1611692 · Cited by 4
Heterogeneity of bacterial host-pathogen interactions across biological scales
Redondo, J. A., Purkait, N., & Paszek, P. (2026) · mSystems · doi:10.1128/msystems.01804-25 · Cited by 3
Melanoma - Standard of Care, Challenges, and Updates in Clinical Research
Maciá, S., & Castañón, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100843 · Cited by 3
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
del Rio, M., de Juan, C. Y.-D., Roncador, G., Caleiras, E. J., Estebán, R. Á., Pérez‐Simón, J. A., & Rodríguez-Barbosa, J.-I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113858 · Cited by 3
Novel Immune Therapies for Renal Cell Carcinoma
Saad, E., Saliby, R. M., Labaki, C., Xu, W. V., Viswanathan, S. R., Braun, D. A., & Bakouny, Z. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.023 · Cited by 3
Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy
Ma, S., Barr, T., & Yu, J. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_3 · Cited by 3
Prognostic biomarker CPEB3 and its associations with immune infiltration in clear cell renal cell carcinoma
Hong, H., Shi, X., Ou, W., & Ou, P. (2024) · Biomedical Reports · doi:10.3892/br.2024.1751 · Cited by 3
Immunemodulation and Cancer
Liu, J., & Huang, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-50977-3_3 · Cited by 3
Role of co‑inhibitory molecules in the treatment of psoriasis (Review)
Yao, Y., Zeng, L., Huang, X., Zhang, J., Zhang, G., & Wang, L. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12497 · Cited by 3
Parkin paves the path to antitumor immunity: Expanding Parkin’s role as a tumor suppressor
Kim, H., & Ronai, Z. A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci185838 · Cited by 3
LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study
Aygün, M. İ. Ş., & Yalçın, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03836-3 · Cited by 3
An activin receptor-like kinase 1–governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases
Talkhoncheh, M. S., Sjölund, J., Bolívar, P., Kurzejamska, E., Cordero, E., Pagès, T. V., Larsson, S., Lehn, S., Frimannsson, G., Ingesson, V., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183086 · Cited by 4
Blocking Tim-3 enhances CD8 + T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation
Wu, N., Pei, X., Cai, W., Ye, X., & Lu, W. (2025) · International Journal of Hyperthermia · doi:10.1080/02656736.2025.2516502 · Cited by 3
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
Zheng, R., Li, Y., Shi, K., Pan, Y., Liu, K., Song, J., & Li, L. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101206 · Cited by 4
Checkpoint agonists — immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis
Baroz, A. R., Lee, D. K., Maverakis, N., Raychaudhuri, S. P., & Raychaudhuri, S. P. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102641 · Cited by 3
Preclinical Studies of PROTACs in Hematological Malignancies
Fuchs, O., & Bokorová, R. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210308111546 · Cited by 3
Identification of Cell Surface Molecules That Determine the Macrophage Activation Threshold Associated With an Early Stage of Malignant Transformation
Jacqueline, C. M., Dracz, M. T., Boothman, S. M., Minden, J. S., Gottschalk, R. A., & Finn, O. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749597 · Cited by 3
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Wael, M., Wael, M., Hosam, M., Youssef, A., Ellackany, R., & Alzahabi, A. (2022) · Radiotherapy and Clinical Oncology · doi:10.31487/j.rco.2022.01.01 · Cited by 2
Multiple Protein Biomarkers and Different Treatment Strategies for Colorectal Carcinoma: A Comprehensive Prospective
Chakraborty, B., Agarwal, S., Kori, S. K., Das, R., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230505165031 · Cited by 3
Transcriptome sequencing and miRNA-mRNA network construction in exosome of macrophage M2 in stomach adenocarcinoma
Pan, D., Li, Z., Lin, X., & Li, L. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03070-1 · Cited by 4
Post-therapeutic microRNA-146a in liquid biopsies may determine prognosis in metastatic gastrointestinal cancer patients receiving 90Y-radioembolization
Hirner-Eppeneder, H., Öcal, E., Stechele, M., Öcal, O., Gu, S., Kimm, M. A., Wildgruber, M., Salvermoser, L., Kazmierczak, P. M., Corradini, S., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05185-0 · Cited by 3

Authors: Wolf, Y., Anderson, A. C., & Kuchroo, V. K.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Kuchroo, Vijay K.
ORCID: Wolf, Yochai
Anderson, Ana C.
Kuchroo, Vijay K.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2019-11-01
Volume: 20
Issue: 3
Pages: 173-185
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/s41577-019-0224-6
PMC: PMC7327798
OpenAlex: W2985205513
Cited by: 959
References: 159
Citations by year: 2026: 98 · 2025: 140 · 2024: 191 · 2023: 160 · 2022: 183 · 2021: 142 · 2020: 44
FWCI: 8.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (R01CA187975)
National Institute of Allergy and Infectious Diseases (P01AI073748, P01AI056299, P01AI039671)
National Institute of Neurological Disorders and Stroke (R01NS045937)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Keywords: TIM-3, inhibitory receptors, co-inhibitory receptors, immune checkpoint, T cell exhaustion, loss-of-function mutations, antitumor immunity, chronic viral infection, cancer immunotherapy
MeSH terms: Hepatitis A Virus Cellular Receptor 2, Animals, Clinical Trials as Topic, Humans, Signal Transduction, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TIM3 comes of age as an inhibitory receptor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks